Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer - Concepedia

Concepedia

Publication | Closed Access

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

27

Citations

0

References

2023

Year

Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky,

Journal of Clinical Oncology

Abstract

Panitumumab monotherapy efficacy in mCRC is confined to patients with WT <i>KRAS</i> tumors. <i>KRAS</i> status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.